12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

Ascend Biopharmaceuticals, Transgene deal

Transgene granted Ascend rights to develop and commercialize TG1042 ( ASN-002) to treat basal cell carcinoma, bladder cancer and...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >